GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (ASX:TRI) » Definitions » Net Change in Cash

TrivarX (ASX:TRI) Net Change in Cash : A$-0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is TrivarX Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

TrivarX's Net Change in Cash for the six months ended in Dec. 2023 was A$0.10 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01 Mil.

TrivarX Net Change in Cash Historical Data

The historical data trend for TrivarX's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX Net Change in Cash Chart

TrivarX Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.79 -0.52 1.50 -1.28 -0.82

TrivarX Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.87 -0.41 -0.72 -0.10 0.10

TrivarX Net Change in Cash Calculation

TrivarX's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.932+-2.259+2.467+-0.095
=-0.82

TrivarX's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.464+-1.35+2.913+-0.003
=0.10

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TrivarX Net Change in Cash Related Terms

Thank you for viewing the detailed overview of TrivarX's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

TrivarX (ASX:TRI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (ASX:TRI) » Definitions » Net Change in Cash
Comparable Companies
ASX:VFX ASX:HIQ ASX:PHX ASX:TD1 ASX:GLH ASX:SHG ASX:IME ASX:ICR ASX:CTQ ASX:OPL GEHC VEEV SOLV ASX:PME HQY TSE:2413 RCM DOCS TXG CERT
Traded in Other Exchanges
MDBIF:USA
Address
647 Beaufort Street, Mount Lawley, WA, AUS, 6050
Website
https://www.medibio.com.au
TrivarX Ltd Formerly Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets; Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.